Institution
Mercy Health Partners
Healthcare•Lorain, Ohio, United States•
About: Mercy Health Partners is a healthcare organization based out in Lorain, Ohio, United States. It is known for research contribution in the topics: Population & Percutaneous tibial nerve stimulation. The organization has 57 authors who have published 64 publications receiving 4848 citations.
Topics: Population, Percutaneous tibial nerve stimulation, Overactive bladder, Urinary incontinence, MEDLINE
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Providing specific definitions for compliance and persistence is important for sound quantitative expressions of patients' drug dosing histories and their explanatory power for clinical and economic events and adoption by health outcomes researchers will provide a consistent framework and lexicon for research.
1,920 citations
••
Brown University1, Université catholique de Louvain2, Scott & White Hospital3, University of Pittsburgh4, University of Paris5, François Rabelais University6, Tufts University7, Mercy Health Partners8, Charles University in Prague9, München Klinik Bogenhausen10, China Medical University (Taiwan)11, Ghent University12, Keio University13, University of Miami14, University of Nebraska Medical Center15, Eisai16, Memorial Hospital of Rhode Island17, Université libre de Bruxelles18
TL;DR: Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality, and no significant differences were observed in any of the prespecified subgroups.
Abstract: Importance Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor. LPS is a major component of the outer membrane of gram-negative bacteria and is a potent activator of the acute inflammatory response. Objective To determine if eritoran, a TLR4 antagonist, would significantly reduce sepsis-induced mortality. Design, Setting, and Participants We performed a randomized, double-blind, placebo-controlled, multinational phase 3 trial in 197 intensive care units. Patients were enrolled from June 2006 to September 2010 and final follow-up was completed in September 2011. Interventions Patients with severe sepsis (n = 1961) were randomized and treated within 12 hours of onset of first organ dysfunction in a 2:1 ratio with a 6-day course of either eritoran tetrasodium (105 mg total) or placebo, with n = 1304 and n = 657 patients, respectively. Main Outcome Measures The primary end point was 28-day all-cause mortality. The secondary end points were all-cause mortality at 3, 6, and 12 months after beginning treatment. Results Baseline characteristics of the 2 study groups were similar. In the modified intent-to-treat analysis (randomized patients who received at least 1 dose) there was no significant difference in the primary end point of 28-day all-cause mortality with 28.1% (366/1304) in the eritoran group vs 26.9% (177/657) in the placebo group (P = .59; hazard ratio, 1.05; 95% CI, 0.88-1.26; difference in mortality rate, −1.1; 95% CI, −5.3 to 3.1) or in the key secondary end point of 1-year all-cause mortality with 44.1% (290/657) in the eritoran group vs 43.3% (565/1304) in the placebo group, Kaplan-Meier analysis of time to death by 1 year, P = .79 (hazard ratio, 0.98; 0.85-1.13). No significant differences were observed in any of the prespecified subgroups. Adverse events, including secondary infection rates, did not differ between study groups. Conclusions and Relevance Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality. Trial Registration clinicaltrials.gov Identifier: NCT00334828
617 citations
••
TL;DR: The compelling efficacy of percutaneous tibial nerve stimulation demonstrated in this trial is consistent with other recently published reports and supports the use of peripheral neuromodulation therapy for overactive bladder.
425 citations
••
TL;DR: This multicenter, randomized trial demonstrates that percutaneous tibial nerve stimulation is safe with statistically significant improvements in patient assessment of overactive bladder symptoms, and with objective effectiveness comparable to that of pharmacotherapy.
348 citations
••
Christopher J L Murray1, Charlton S K H Callender1, Xie Rachel Kulikoff1, Vinay Srinivasan1 +1092 more•Institutions (424)
TL;DR: This work estimated population in 195 locations by single year of age and single calendar year from 1950 to 2017 with standardised and replicable methods and used the cohort-component method of population projection, with inputs of fertility, mortality, population, and migration data.
287 citations
Authors
Showing all 57 results
Name | H-index | Papers | Citations |
---|---|---|---|
Elad I. Levy | 73 | 613 | 31272 |
Charles J. Glueck | 71 | 383 | 18623 |
Ping Wang | 28 | 53 | 3192 |
Michael C. Plewa | 19 | 36 | 1480 |
Timothy R. Jordan | 17 | 46 | 935 |
Osama O. Zaidat | 13 | 53 | 1020 |
J. Kevin McGraw | 13 | 22 | 1094 |
Betro T. Sadek | 12 | 19 | 549 |
Nancy Buderer | 10 | 18 | 778 |
Eugene Lin | 9 | 18 | 295 |
Leslie Wooldridge | 7 | 17 | 1170 |
Haseeb Nawaz | 7 | 7 | 2509 |
Mark Micale | 6 | 16 | 185 |
Gary N. Fox | 5 | 15 | 92 |
Luis Jauregui | 3 | 3 | 1219 |